Skip to content

Homeopathic medicines for problems related to recurrent stool

An open-label, Randomized, Placebo-controlled Trial to Evaluate the Efficacy of Gambogia and Individualized Homoeopathic Medicines in Irritable Bowel Syndrome

Status
Recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/11/021916
Enrollment
111
Registered
2019-11-07
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K580- Irritable bowel syndrome with diarrhea

Interventions

Intervention1: Homeopathic medicine Gambogia in centesimal potencies: Intervention is planned as administering homeopathic medicine Gambogia in centesimal potencies. In centesimal scale, each dose sha
dosage and repetition depending upon the individual requirement of the cases. The medicines have been procured from a Good Manufacturing Practice (GMP)-certified firm. The patients will be advised to

Sponsors

National Institute of Homoeopathy
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a) Patients suffering from IBS, as per Rome IV diagnostic criteria b) Both sexes c) Age 18-65 years d) Literate patients with ability to read Bengali and/or English e) Patients willing to participate in the study and giving written informed consent.

Exclusion criteria

Exclusion criteria: a) Patients who are too unwell to take part b) Inability to read patient information sheets and/or denied consent to take part c) Diagnosed cases of unstable psychiatric complaints or other systemic diseases affecting quality of life d) Any major gastro-intestinal surgery in last 6 months e) Currently receiving standard therapy for IBS and/or homeopathic treatment for any chronic condition(s) f) Pregnant and lactating women g) Self-reported immune compromised conditions h) Substance abuse and/or dependence

Design outcomes

Primary

MeasureTime frame
IBS Quality of Life questionnaireTimepoint: Baseline, every month, up to 3 months

Secondary

MeasureTime frame
EQ-5D-5L questionnaire score and VAS measureTimepoint: Baseline, every month, up to 3 months;IBS symptom severity scoreTimepoint: Baseline, every month, up to 3 months

Countries

India

Contacts

Public ContactUsha Ghelani Uchat

National Institute of Homoeopathy

dr.ushauchatnih2017@gmail.com9830966265

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026